AiCuris’ novel resistance breaking HIV compound AIC292 in phase I
Following oral administration the compound was generally well tolerated and the resulting pharmacokinetic profile was indicative of the potential for a once daily dosing regime. Commenting on the results Prof. Dr. Helga Rübsamen-Schaeff, CEO of AiCuris, stated ‘’We are very pleased about these results. Due to the chronic course of an HIV infection once daily dosing is one of the key prerequisites for a modern HIV drug in addition to good efficacy and tolerability.”
Like other compounds from AiCuris, AIC292 has a resistance-breaking profile. Prof. Rübsamen-Schaeff: “With this compound we have demonstrated once again the ability to generate innovative and attractive candidates for clinical development with our in house research in collaboration with external partners.”
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.